Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.
Jennifer E. Amengual, MD
Advertisement
Articles by Jennifer E. Amengual, MD
Jennifer E. Amengual, MD, discusses the study she presented at the 2013 American Society of Hematology (ASH) Annual Meeting. The trial analyzed dual targeting with the HDAC inhibitor ACY-1215 and bortezomib in preclinical models of lymphoma.
Advertisement
Latest Updated Articles
Dual Targeting With an HDAC 6 Inhibitor and Bortezomib in LymphomaDecember 10th 2013
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5